Bioclinica Provides RBM to Japan-Based CRO
EPS, a CRO based in Tokyo, Japan, has chosen Bioclinica’s COMPASS technology and professional services as its risk-based monitoring (RBM) solution for clinical trials in Japan. EPS President and Representative Director Hisashi Tanaka said in a release that the company wants to implement effective RBM services consistent with global regulatory authority initiatives. The COMPASS solution was chosen for many reasons, including a library of 44 standard KRIs and an ability to add additional custom KRIs; tracking and visualization at the study and site level, and robust alert and action recommendations.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
